Bernard Roubert
Overview
Explore the profile of Bernard Roubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, et al.
Med Oncol
. 2014 Nov;
31(12):302.
PMID: 25373320
This randomized trial evaluated ferric carboxymaltose without erythropoiesis-stimulating agents (ESA) for correction of anemia in cancer patients with functional iron deficiency. Patients on treatment for indolent lymphoid malignancies, who had...
12.
Ponikowski P, Van Veldhuisen D, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al.
Eur Heart J
. 2014 Sep;
36(11):657-68.
PMID: 25176939
Aim: The aim of this study was to evaluate the benefits and safety of long-term i.v. iron therapy in iron-deficient patients with heart failure (HF). Methods And Results: CONFIRM-HF was...
13.
Macdougall I, Bock A, Carrera F, Eckardt K, Gaillard C, Van Wyck D, et al.
Nephrol Dial Transplant
. 2014 Jun;
29(11):2075-84.
PMID: 24891437
Background: The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. Methods: Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease...
14.
Macdougall I, Bock A, Carrera F, Eckardt K, Gaillard C, Van Wyck D, et al.
Nephrol Dial Transplant
. 2013 Oct;
29(4):843-50.
PMID: 24170814
Background: Rigorous data are sparse concerning the optimal route of administration and dosing strategy for iron therapy with or without concomitant erythropoiesis-stimulating agent (ESA) therapy for the management of iron...
15.
Gattermann N, Finelli C, Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al.
Haematologica
. 2012 Mar;
97(9):1364-71.
PMID: 22419577
Background: Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on there reductions/improvements have been limited...
16.
Pennell D, Porter J, Cappellini M, Chan L, El-Beshlawy A, Aydinok Y, et al.
Haematologica
. 2012 Jan;
97(6):842-8.
PMID: 22271905
Background: Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design And Methods: Seventy-one patients in the EPIC cardiac substudy elected to...
17.
Taher A, Elalfy M, Al Zir K, Daar S, Al Jefri A, Habr D, et al.
Eur J Haematol
. 2011 Jun;
87(4):355-65.
PMID: 21668502
Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC)....
18.
Taher A, Elalfy M, Al Zir K, Daar S, Al Jefri A, Habr D, et al.
Eur J Haematol
. 2011 Jun;
87(4):349-54.
PMID: 21668501
This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n = 231). Mean liver iron concentrations...
19.
Porter J, Lin K, Beris P, Forni G, Taher A, Habr D, et al.
Eur J Haematol
. 2011 Jun;
87(4):338-48.
PMID: 21649735
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation therapy are similar, irrespective of the underlying condition. However, data are limited for rare transfusion-dependent anaemias,...
20.
Viprakasit V, Ibrahim H, Ha S, Ho P, Li C, Chan L, et al.
Int J Hematol
. 2011 Mar;
93(3):319-328.
PMID: 21374076
Although thalassaemia is highly prevalent in the Asia-Pacific region, clinical data on efficacy and safety profiles of deferasirox in patients from this region are rather limited. Recently, data from the...